Bold Steps Needed to Correct Course in US Drug Policies
Moving the United States beyond the opioid overdose crisis and pernicious inequities in law enforcement requires bold, innovative solutions.
Pharmaceuticals
-
Read more: Bold Steps Needed to Correct Course in US Drug Policies -
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from the month of February 2021.
-
Read more: The Patent Trial and Appeal Board Returns to the Supreme Court The Patent Trial and Appeal Board Returns to the Supreme Court
How the Court decides United States v. Arthrex will have important implications for patent law and for administrative law more generally.
-
Read more: How the Government Can Prevent Individuals from Using Wealth to Cut the Vaccine Line How the Government Can Prevent Individuals from Using Wealth to Cut the Vaccine Line
There are several ways government officials can combat the wealth problem without sacrificing the speed at which vaccines are administered.
-
Read more: 3 Challenges to Patents on Therapeutic Monoclonal Antibodies 3 Challenges to Patents on Therapeutic Monoclonal Antibodies
Three developments may have effects on the use of patents to fend off competition for therapeutic monoclonal antibodies.
-
Read more: Ensuring 340B Discounts Trickle Down to Low-Income Patients Ensuring 340B Discounts Trickle Down to Low-Income Patients
Congress must take action to ensure these discounts benefit low-income 340B eligible patients, as intended.
-
Read more: How Can Policymakers Overcome the Hurdles to Scaling up Antibody Manufacturing? How Can Policymakers Overcome the Hurdles to Scaling up Antibody Manufacturing?
The difficult manufacturing issues involved in the therapeutic antibody context, and what might be done to address them.
-
Read more: HHS’s 340B Advisory Opinion: Helpful or Harmful? HHS’s 340B Advisory Opinion: Helpful or Harmful?
A recent advisory opinion released by HHS left many 340B advocates hungry for answers and pharmaceutical manufacturers frustrated.
-
Read more: Why Aren’t Therapeutic Antibodies Being Used More to Treat COVID-19? Why Aren’t Therapeutic Antibodies Being Used More to Treat COVID-19?
The rapid development of therapeutic antibodies is a triumph of biomedical innovation. But they won’t help unless they make it to patients.
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Topics range from an analysis of recent developments in drug-pricing transparency, to an analysis of state-level drug product selection laws.
